Recently, it has been demonstrated that plerixafor can achieve safe and successful mobilization of patients with SCD and produces higher CD34+ cell doses than those that can historically be achieved using traditional BM aspiration.12 The gene discussed is CD34; the disease is Schnyder corneal dystrophy.